WO2004113387A3 - Tumour necrosis factor receptor molecules with reduced immunogenicity - Google Patents

Tumour necrosis factor receptor molecules with reduced immunogenicity Download PDF

Info

Publication number
WO2004113387A3
WO2004113387A3 PCT/EP2004/006838 EP2004006838W WO2004113387A3 WO 2004113387 A3 WO2004113387 A3 WO 2004113387A3 EP 2004006838 W EP2004006838 W EP 2004006838W WO 2004113387 A3 WO2004113387 A3 WO 2004113387A3
Authority
WO
WIPO (PCT)
Prior art keywords
necrosis factor
factor receptor
receptor molecules
reduced immunogenicity
tumour necrosis
Prior art date
Application number
PCT/EP2004/006838
Other languages
French (fr)
Other versions
WO2004113387A2 (en
Inventor
Matthew Baker
Koen Hellendoorn
Original Assignee
Merck Patent Gmbh
Matthew Baker
Koen Hellendoorn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Matthew Baker, Koen Hellendoorn filed Critical Merck Patent Gmbh
Priority to EP04740252A priority Critical patent/EP1636264A2/en
Publication of WO2004113387A2 publication Critical patent/WO2004113387A2/en
Publication of WO2004113387A3 publication Critical patent/WO2004113387A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to the modification of human soluble tumor necrosis factor receptor type 1 (sTNFR1) to result in sTNFR1 proteins, preferably fusion proteins comprising an immunoglobulin heavy chain constant region (Fc domain) and modified human sTNFR-I. These molecules are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo by elimination or deletion of T-cell epitopes. The invention relates furthermore to T-cell epitope peptides derived from non-modified human sTNFR-I.
PCT/EP2004/006838 2003-06-24 2004-06-24 Tumour necrosis factor receptor molecules with reduced immunogenicity WO2004113387A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04740252A EP1636264A2 (en) 2003-06-24 2004-06-24 Tumour necrosis factor receptor molecules with reduced immunogenicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03014121 2003-06-24
EP03014121.2 2003-06-24

Publications (2)

Publication Number Publication Date
WO2004113387A2 WO2004113387A2 (en) 2004-12-29
WO2004113387A3 true WO2004113387A3 (en) 2005-03-17

Family

ID=33522261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/006838 WO2004113387A2 (en) 2003-06-24 2004-06-24 Tumour necrosis factor receptor molecules with reduced immunogenicity

Country Status (2)

Country Link
EP (1) EP1636264A2 (en)
WO (1) WO2004113387A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5620626B2 (en) 2005-03-31 2014-11-05 中外製薬株式会社 Polypeptide production method by association control
CN1309740C (en) * 2005-10-20 2007-04-11 高基民 Soluble tumour necrosis factor receptor II-
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
ES2413804T3 (en) 2006-05-19 2013-07-17 Alcon Research, Ltd. RNAi-mediated inhibition of states related to tumor necrosis factor-alpha
AU2014200636B2 (en) * 2007-09-26 2016-02-25 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
KR102467302B1 (en) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 Modified antibody constant region
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
DK2342220T3 (en) * 2008-10-06 2021-08-09 Univ British Columbia METHODS AND SYSTEMS FOR PREDICTING MISFOLD PROTEIN PITOPES
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
US8722615B2 (en) 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
CA2922704A1 (en) 2013-05-24 2014-11-27 Neil R. Cashman Cell senescence markers as diagnostic and therapeutic targets
RU2758952C1 (en) 2013-09-27 2021-11-03 Чугаи Сейяку Кабусики Кайся Method for producing a polypeptide heteromultimer
BR112017014067B1 (en) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha uses of an il-6 receptor antibody to treat il-6-related diseases
JP7082484B2 (en) 2015-04-01 2022-06-08 中外製薬株式会社 Method for Producing Polypeptide Heterogeneous Multimer
KR20180091918A (en) 2015-12-28 2018-08-16 추가이 세이야쿠 가부시키가이샤 A method for efficiently purifying the Fc region-containing polypeptide
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018203545A1 (en) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
JP2021518343A (en) 2018-03-15 2021-08-02 中外製薬株式会社 Anti-dengue virus antibody with cross-reactivity to Zika virus and how to use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2003104263A2 (en) * 2002-05-01 2003-12-18 Genencor International, Inc. Cytokines and cytokine receptors with reduced immunogenicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2003104263A2 (en) * 2002-05-01 2003-12-18 Genencor International, Inc. Cytokines and cytokine receptors with reduced immunogenicity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTEN URS ET AL: "Immune response to a recombinant human TNFR55-IgG1 fusion protein: Auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities", HUMAN IMMUNOLOGY, vol. 60, no. 9, September 1999 (1999-09-01), pages 774 - 790, XP002314027, ISSN: 0198-8859 *
GALON J ET AL: "TNFRSF1A mutations and autoinflammatory syndromes", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 12, no. 4, 1 August 2000 (2000-08-01), pages 479 - 486, XP004257708, ISSN: 0952-7915 *
ROSENBERG J J ET AL: "Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon.", JOURNAL OF APPLIED PHYSIOLOGY (BETHESDA, MD. : 1985) NOV 2001, vol. 91, no. 5, November 2001 (2001-11-01), pages 2213 - 2223, XP002314026, ISSN: 8750-7587 *
TODD IAN ET AL: "Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour", IMMUNOLOGY, vol. 113, no. 1, September 2004 (2004-09-01), pages 65 - 79, XP002314028, ISSN: 0019-2805 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant

Also Published As

Publication number Publication date
WO2004113387A2 (en) 2004-12-29
EP1636264A2 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
WO2004113387A3 (en) Tumour necrosis factor receptor molecules with reduced immunogenicity
WO2003042247A3 (en) Modified anti-tnf alpha antibody
WO2003020764A3 (en) Modified factor ix
WO2006083301A3 (en) Immunogenic compositions comprising hmgb1 polypeptides
WO2009041613A1 (en) Modified antibody constant region
JP2021167352A (en) METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOBULIN Fc FRAGMENT LINKAGE
WO2007094842A3 (en) Binding polypeptides and uses thereof
WO2002079232A3 (en) Reducing the immunogenicity of fusion proteins
WO2002098897A3 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2001092337A3 (en) Soluble ctla4 mutant molecules and uses thereof
DE602006019446D1 (en) TUMOR-ASSOCIATED PEPTIDES AND ASSOCIATED VACCINE AGAINST CANCER BINDING TO HUMAN LEUKOCYTANTANT (HLA) CLASS I OR II MOLECULES
ATE439375T1 (en) IMMUNOGENIC T-HELPER EPITOPES OF HUMAN TUMOR ANTIGENS AND THEIR USE IN IMMUNOTHERAPEUTIC METHODS
WO2005111072A3 (en) Notch-based fusion proteins and uses thereof
DE60235041D1 (en) AND YOUR USE
WO2007016150A3 (en) Mutated pseudomonas exotoxins with reduced antigenicity
WO2002081646A3 (en) Epitope sequences
WO2006010057A3 (en) Therapeutic peptides
HK1083026A1 (en) Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination
EP2283868A3 (en) Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer
WO2007011216A3 (en) Bifunctional protein anchors
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
PL371278A1 (en) Modified factor viii
WO2002098360A3 (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
EP2193804A3 (en) Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
AU2020279393A1 (en) Methods of treating liver disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004740252

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004740252

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004740252

Country of ref document: EP